
Annual report 2025
added 03-04-2026
Viemed Healthcare Net Debt 2011-2026 | VMD
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Viemed Healthcare
| 2025 | 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.01 M | -13.1 M | -6.16 M | -22.6 M | -23.3 M | -3.98 M | -6.99 M | 81 K | 2.15 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.15 M | -23.3 M | -8.33 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
EDAP TMS S.A.
EDAP
|
-22.8 M | $ 3.28 | - | $ 123 M | ||
|
Electromed
ELMD
|
-10.5 M | $ 25.74 | - | $ 218 M | ||
|
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | ||
|
Globus Medical
GMED
|
-511 M | $ 90.74 | - | $ 12.3 B | ||
|
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | ||
|
Helius Medical Technologies
HSDT
|
-5.12 M | $ 2.08 | - | $ 1.26 M | ||
|
Aziyo Biologics
AZYO
|
-32.4 M | - | 1.37 % | $ 20.5 M | ||
|
AdaptHealth Corp.
AHCO
|
1.64 B | $ 13.38 | - | $ 1.81 B | ||
|
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
BIOLASE
BIOL
|
6.1 M | - | -13.19 % | $ 166 K | ||
|
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | ||
|
Pulmonx Corporation
LUNG
|
-31.6 M | $ 1.23 | - | $ 50 M | ||
|
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | ||
|
Orthofix Medical
OFIX
|
78.5 M | $ 11.91 | - | $ 472 M | ||
|
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | ||
|
Insulet Corporation
PODD
|
468 M | $ 182.87 | - | $ 12.9 B | ||
|
Cardiovascular Systems
CSII
|
-64.6 M | - | 0.15 % | $ 844 M | ||
|
Cytosorbents Corporation
CTSO
|
11 M | $ 0.6 | -1.96 % | $ 37.3 M | ||
|
Sintx Technologies
SINT
|
-898 K | $ 2.15 | - | $ 5.96 M | ||
|
ClearPoint Neuro
CLPT
|
3.85 M | $ 11.08 | - | $ 314 M | ||
|
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
-97.8 M | - | - | $ 10.2 M | ||
|
Stryker Corporation
SYK
|
11 B | $ 321.43 | -0.02 % | $ 123 B | ||
|
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | ||
|
Tactile Systems Technology
TCMD
|
-75.4 M | $ 23.57 | - | $ 539 M | ||
|
TELA Bio
TELA
|
5.33 M | $ 0.78 | - | $ 36.6 M | ||
|
Second Sight Medical Products
EYES
|
2.62 M | - | -0.97 % | $ 54.4 M | ||
|
TransMedics Group
TMDX
|
-32.3 M | $ 101.26 | - | $ 3.44 B | ||
|
Tandem Diabetes Care
TNDM
|
239 M | $ 18.63 | - | $ 1.27 B | ||
|
GBS
GBS
|
-4.38 M | - | -0.57 % | $ 7.12 M | ||
|
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M | ||
|
Varex Imaging Corporation
VREX
|
225 M | $ 12.07 | - | $ 500 M | ||
|
Butterfly Network
BFLY
|
-65.9 M | $ 5.16 | - | $ 1.09 B | ||
|
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | ||
|
Vivos Therapeutics
VVOS
|
-888 K | $ 0.85 | - | $ 8.73 M | ||
|
Beyond Air
XAIR
|
-2.78 M | $ 0.51 | - | $ 34.5 M | ||
|
OrthoPediatrics Corp.
KIDS
|
83.3 M | $ 15.14 | - | $ 355 M | ||
|
Delcath Systems
DCTH
|
-42.5 M | $ 10.55 | - | $ 378 M | ||
|
Xtant Medical Holdings
XTNT
|
-5.4 M | $ 0.55 | -1.78 % | $ 76.7 M | ||
|
Zimmer Biomet Holdings
ZBH
|
4.87 B | $ 82.8 | - | $ 16.8 B | ||
|
IRIDEX Corporation
IRIX
|
-5.23 M | $ 1.04 | - | $ 17.6 M | ||
|
CONMED Corporation
CNMD
|
802 M | $ 36.79 | - | $ 1.14 B |